Propria

Propria was founded with the mission to advance cardiac research by making engineered heart tissue (EHT) more powerful and accessible to scientists. The company focuses on providing cardiac contractility testing services, offering products such as the MyoPod™ Engineered Heart Tissues and the MyoLab™ platform. These tools are designed to enable researchers to model diseases, profile contractile function, and assess functional cardiac reserve, thereby enhancing the study of heart conditions and potential treatments.

Notable individuals affiliated with Propria include leading scientists and researchers in the field of cardiac biology. The company has attracted significant interest from investors focused on biotech innovations. Key achievements include the development and successful implementation of their proprietary MyoPod™ and MyoLab™ technologies, which have been widely adopted in cardiac research labs. Propria's impact is evident in its contribution to more accurate and efficient cardiac disease modeling, ultimately aiding in the development of new therapies and improving patient outcomes.